10.29.13
Sailash Patel has been appointed chief financial officer at Furiex Pharmaceuticals, Inc., effective November 15, 2013. Mr. Patel replaces Marshall Woodworth, who has resigned to pursue other interests, but will remain to assist with the transition.
Mr. Patel currently serves as vice president of strategic development at Furiex, a role he held since its spin-off from PPD LLC, where he oversees corporate development, investor relations and strategic planning. Previously, Mr. Patel served as vice president of strategic development for PPD, where he ran corporate strategy development and was responsible for the company’s acquisitions and licensing activities.
“Mr. Patel has an impressive track record in the biotech and pharmaceutical industry and brings a unique set of talents to the chief financial officer role as we continue to progress our product portfolio,” said June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex. “In his prior roles, Sailash has proven himself as a key member of leadership teams, driving financial strategy and deal making.”
Mr. Patel currently serves as vice president of strategic development at Furiex, a role he held since its spin-off from PPD LLC, where he oversees corporate development, investor relations and strategic planning. Previously, Mr. Patel served as vice president of strategic development for PPD, where he ran corporate strategy development and was responsible for the company’s acquisitions and licensing activities.
“Mr. Patel has an impressive track record in the biotech and pharmaceutical industry and brings a unique set of talents to the chief financial officer role as we continue to progress our product portfolio,” said June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex. “In his prior roles, Sailash has proven himself as a key member of leadership teams, driving financial strategy and deal making.”